James Ford

Biography

Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention. Dr. Ford graduated in 1984 Magna Cum Laude (Biology) from Yale University where he later received his M.D. degree from the School of Medicine in 1989. He was a internal medicine resident (1989-91), Clinical Fellow in Medical Oncology (1991-94), Research Fellow of Biological Sciences (1993-97) at Stanford, and joined the faculty in 1998. He is currently Professor of Medicine (Oncology) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford University Medical Center.

Dr. Ford’s research goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He studies the role of the p53 and BRCA1 tumor suppressor genes in DNA repair, and uses techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies. Dr. Ford’s clinical interests include the diagnosis and treatment of patients with a hereditary pre-disposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes for prevention and early diagnosis of cancer in high-risk individuals and populations. He has recently been named the Director of Stanford’s new Cancer Genomics Program, performing next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies, and directs the Molecular Tumor Board.

Dr. Ford is an editor of numerous scientific journals, including Cancer Research, DNA Repair, and PLoS Genetics. He has recently been named the founding Editor-in-Chief of JCO Precision Oncology.

.

View Full Biography

Professional Summary

Education & Certifications

Medical Education: Yale School Of Medicine (1989) CT
Fellowship: Stanford University Hematology and Oncology Fellowship (1994) CA
Residency: Stanford University Internal Medicine Residency (1991) CA
- Internship: Stanford University Internal Medicine Residency (1990) CA
- M.D., Yale Medical School, Medicine (1989)
- Board Certification: American Board of Internal Medicine, Medical Oncology (2005)
- Maintenance of Certification, Medical Oncology, American Board of Internal Medicine (2015)

Honors & Awards

Council Chair, California Breast Cancer Research Program (2009 - 10)
Editor-in-Chief, JCO Precision Oncology Journal (2016 - 2020)
FASCO, ASCO (2017)
- Medical Oncology, Best Doctors in America (2013 -)
- Member, Western Society for Clinical Investigation (2007)
- Top Doctor for Cancer, Castle Connolly (2008 -)

Memberships

Board of Directors, Gastric Cancer Foundation (2008 - 2017)
Scientific Advisory Board, V Foundation (2006 - Present)
Member, ASCO Cancer Prevention Committee (2013 - 2016)

Administrative Appointments

Associate Director of Education and Training, Stanford Cancer Institute (2018 - Present)
Director, Oncology Fellowship Training Program (2002 - 2015)
Director, Stanford Clinical Cancer Genomics (2013 - Present)
- Founding Director, Stanford Clinical Cancer Genetics Program (2000 - Present)

Publications

Chemoradiotherapy in the management of localized tumors of the pancreas
Poen, J. C., Ford, J. M., & Niederhuber, J. E. (1999). Chemoradiotherapy in the management of localized tumors of the pancreas. ANNALS OF SURGICAL ONCOLOGY, 6(1), 117–122.
p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes
Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A., Amundson, S. A., Seo, Y. R., … Fornace, A. J. (2000). p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes. MOLECULAR AND CELLULAR BIOLOGY, 20(10), 3705–14.
Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice
Ichikawa, M., Nakane, H., Marra, G., Corti, C., Jiricny, J., Fitch, M., … Tanaka, K. (2000). Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice. MUTATION RESEARCH-DNA REPAIR, 459(4), 285–98.
- Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis
  Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (2000). Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. MOLECULAR CELL, 5(4), 737–44.
- Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells
  Bowman, K. K., Sicard, D. M., Ford, J. M., & Hanawalt, P. C. (2000). Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. MOLECULAR CARCINOGENESIS, 29(1), 17–24.
- Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53
  Lopez, C. D., Ao, Y., Rohde, L. H., Perez, T. D., O'Connor, D. J., Lu, X., … Naumovski, L. (2000). Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. MOLECULAR AND CELLULAR BIOLOGY, 20(21), 8018–25.
- Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
  Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., & Poen, J. C. (2000). Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(5), 1483–87.
- Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report
  Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., Oberhelman, H. A., & Bastidas, A. J. (2001). Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report. ARCHIVES OF SURGERY, 136(1), 65–69.
- Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
  Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., Oberbelman, H., … Bastidas, J. A. (2001). Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. JOURNAL OF GASTROINTESTINAL SURGERY, 5(1), 27–35.
- Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer
  Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., & Fisher, G. A. (2001). Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 24(2), 155–59.
- The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts
  Adimoolam, S., Lin, C. X., & Ford, J. M. (2001). The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(28), 25813–22.
- Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer
  Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., Bastidas, A. J., … Fisher, G. (2001). Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. DISEASES OF THE COLON & RECTUM, 44(1), 52–58.
- BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
  Hartman, A. R., & Ford, J. M. (2002). BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. NATURE GENETICS, 32(1), 180–84.
- p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
  Adimoolam, S., & Ford, J. M. (2002). p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(20), 12985–90.
- DNA Damage, Repair, and Diseases.
  Wiesmüller, L., Ford, J. M., & Schiestl, R. H. (2002). DNA Damage, Repair, and Diseases. Journal of Biomedicine & Biotechnology, 2(2), 45.
- Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer
  Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., Koong, A., … Fisher, G. (2003). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55(1), 132–37.
- p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo
  Fitch, M. E., Cross, I. V., & Ford, J. M. (2003). p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. CARCINOGENESIS, 24(5), 843–50.
- The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts
  Fitch, M. E., Cross, I. V., Turner, S. J., Adimoolam, S., Lin, C. X., Williams, K. G., & Ford, J. A. (2003). The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA REPAIR, 2(7), 819–26.
- Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression
  Karlsson, A., Deb-Basu, D., Cherry, A., Turner, S., Ford, J., & Felsher, D. W. (2003). Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(17), 9974–79.
- In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product
  Fitch, M. E., Nakajima, S., Yasui, A., & Ford, J. M. (2003). In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. JOURNAL OF BIOLOGICAL CHEMISTRY, 278(47), 46906–10.
- p53 and regulation of DNA damage recognition during nucleotide excision repair
  Adimoolam, S., & Ford, J. M. (2003). p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA REPAIR, 2(9), 947–54.
- BRCA1 and p53: compensatory roles in DNA repair
  Hartman, A. R., & Ford, J. M. (2003). BRCA1 and p53: compensatory roles in DNA repair. JOURNAL OF MOLECULAR MEDICINE-JMM, 81(11), 700–707.
- Functional characterization of global genomic DNA repair and its implications for cancer
  Hanawalt, P. C., Ford, J. A., & Lloyd, D. R. (2003). Functional characterization of global genomic DNA repair and its implications for cancer. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 544(2-3), 107–14.
- Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
  Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., Dirbas, F. M., … Plevritis, S. K. (2004). Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. CANCER, 100(3), 479–89.
- Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
  Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., Cho, C., … Bastidas, J. A. (2004). Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1017–21.
- Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
  Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., Kingham, K. E., … Hartman, A. R. (2005). Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 14(5), 1082–89.
- Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53
  Ford, J. M. (2005). Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 577(1-2), 195–202.
- Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management
  Suriano, G., Yew, S., Ferreira, P., Senz, J., Kaurah, P., Ford, J. M., … Huntsman, D. G. (2005). Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management. CLINICAL CANCER RESEARCH, 11(15), 5401–9.
- Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
  Kurian, A. W., Hartman, A. R., Mills, M. A., Ford, J. M., Daniel, B. L., & Plevritis, S. K. (2005). Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. HEALTH EXPECTATIONS, 8(3), 221–33.
- Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
  Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., … Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613–19.
- Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
  Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., Kuo, T., … Yang, G. P. (2005). Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), 320–23.
- Genetic/familial high-risk assessment: breast and ovarian.
  Daly, M. B., Axilbund, J. E., Bryant, E., Buys, S., Eng, C., Friedman, S., … Weitzel, J. N. (2006). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network , 4(2), 156–176.
- Colorectal Cancer Screening Clinical Practice Guidelines.
  Levin, B., Barthel, J. S., Burt, R. W., David, D. S., Ford, J. M., Giardiello, F. M., … Winawer, S. J. (2006). Colorectal Cancer Screening Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network , 4(4), 384–420.
- Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling
  D Bomgarden, R., Lupardus, P. J., Soni, D. V., Yee, M.-C., Ford, J. M., & Cimprich, K. A. (2006). Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. EMBO JOURNAL, 25(11), 2605–14.
- A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins
  Chen, X., Zhang, J., Lee, J., Lin, P. S., Ford, J. M., Zheng, N., & Zhou, P. (2006). A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. MOLECULAR CELL, 22(4), 489–99.
- Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study
  Park, J.-G., Kim, D.-W., Hong, C. W., Nam, B.-ho, Shin, Y.-K., Hong, S.-H., … Wijnen, J. (2006). Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. CLINICAL CANCER RESEARCH, 12(11), 3389–93.
- Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma
  Ji, H., Kumm, J., Zhang, M., Farnam, K., Salari, K., Faham, M., … Davis, R. W. (2006). Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. CANCER RESEARCH, 66(16), 7910–19.
- Predicting and preventing hereditary colorectal cancer
  Ford, J. M., & Whittemore, A. S. (2006). Predicting and preventing hereditary colorectal cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 296(12), 1521–23.
- Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
  Alli, E., Yang, J.-M., Ford, J. M., & Hait, W. N. (2007). Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. MOLECULAR PHARMACOLOGY, 71(5), 1233–40.
- Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
  Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A.-R., Mills, M. A., Plevritis, S. K., … Daniel, B. L. (2007). Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. BREAST JOURNAL, 13(3), 281–86.
- CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer
  Norton, J. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Huntsman, D. G., … Ford, J. M. (2007). CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer. ANNALS OF SURGERY, 245(6), 873–79.
- Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer
  Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., … Huntsman, D. (2007). Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 297(21), 2360–72.
- Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family
  Schiffman, J. D., Chun, N., Fisher, P. G., Dahl, G. V., Ford, J. M., & Eggerding, F. A. (2008). Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. PEDIATRIC BLOOD & CANCER, 50(4), 914–16.
- Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family
  Kwong, A., Wong, L. P., Chan, K. Y. K., Ma, E. S. K., Khoo, U. S., & Ford, J. M. (2008). Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. FAMILIAL CANCER, 7(2), 125–133.
- Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays
  Mullins, F. M., Dietz, L., Lay, M., Zehnder, J. L., Ford, J., Chun, N., & Schrijver, I. (2007). Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. GENETICS IN MEDICINE, 9(11), 752–60.
- Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
  Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., & Ford, J. M. (2008). Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. FAMILIAL CANCER, 7(2), 179–86.
- A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature
  Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. A., Kingham, K., & Ford, J. M. (2007). A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature. CANCER GENETICS AND CYTOGENETICS, 179(2), 89–92.
- HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
  Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007). HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 104(49), 19482–87.
- Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology
  Kurian, A. W., Hartman, A.-R., Mills, M. A., Logan, L. J., Sawyer, A. M., Ford, J. M., & Daniel, B. L. (2008). Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. BREAST JOURNAL, 14(2), 211–14.
- Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.
  Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., Huntsman, D. G., … Longacre, T. A. (2008). Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. American Journal of Surgical Pathology, 32(6), 799–809.
- Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
  Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., Ford, J. M., … Koong, A. C. (2008). Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 678–86.
- Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger
  Jensen, K. C., Mariappan, M. R., Putcha, G. V., Husain, A., Chun, N., Ford, J. M., … Longacre, T. A. (2008). Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 32(7), 1029–37.
- Performance of BRCA1/2 mutation prediction models in Asian Americans
  Kurian, A. W., Gong, G. D., Chun, N. M., Mills, M. A., Staton, A. D., Kingham, K. E., … Ford, J. M. (2008). Performance of BRCA1/2 mutation prediction models in Asian Americans. JOURNAL OF CLINICAL ONCOLOGY, 26(29), 4752–58.
- Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery
  Cisco, R. M., Ford, J. M., & Norton, J. A. (2008). Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery. CANCER, 113(7), 1850–56.
- Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
  Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., Fisher, G. A., … Koong, A. C. (2009). Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas. CANCER, 115(3), 665–72.
- Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase
  Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009). Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase. CANCER RESEARCH, 69(8), 3589–96.
- A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer
  Kwong, A., Wong, L. P., Wong, H. N., Law, F. B. F., Ng, E. K. O., Tang, Y. H., … Ford, J. M. (2009). A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. BREAST CANCER RESEARCH AND TREATMENT, 117(3), 683–86.
- The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair
  Lin, P. S., McPherson, L. A., Chen, A. Y., Sage, J., & Ford, J. M. (2009). The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA REPAIR, 8(7), 795–802.
- Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT
  Kim, J., Quon, A., Humke, E., Ford, J. M., & Koong, A. C. (2009). Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT. CLINICAL NUCLEAR MEDICINE, 34(5), 312–13.
- Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
  Kurian, A. W., McClure, L. A., John, E. M., Horn-Ross, P. L., Ford, J. M., & Clarke, C. A. (2009). Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 101(15), 1058–65.
- Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia
  Schiffman, J. D., Wang, Y., McPherson, L. A., Welch, K., Zhang, N., Davis, R., … Ji, H. P. (2009). Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. CANCER GENETICS AND CYTOGENETICS, 193(1), 9–18.
- Pathological response after chemoradiation for T3 rectal cancer.
  Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal Disease , 12(7 Online), e24–30.
- CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES
  Ford, J. M., Bruggemann, E. P., Pastan, I., Gottesman, M. M., & Hait, W. N. (1990). CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES. CANCER RESEARCH, 50(6), 1748–1756.
- Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
  La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., Kunz, P., … Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300–308.
- EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE
  Ford, J. M., Yang, J. M., & Hait, W. N. (1991). EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE. CANCER RESEARCH, 51(1), 67–72.
- Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
  Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., Fisher, G. A., … Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.
- MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS
  Ford, J. M., Hait, W. N., Matlin, S. A., & Benz, C. C. (1991). MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS. CANCER LETTERS, 56(1), 85–94.
- (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
  Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., … Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420–25.
- Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
  Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M.-Y. C., Yu, M., … James, C. D. (2010). Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas. CANCER RESEARCH, 70(2), 512–19.
- Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
  Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605–13.
- High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients
  Kwong, A., Ng, E. K. O., Law, F. B. F., Wong, L. P., To, M. Y., Cheung, M. T., … Ma, E. S. K. (2010). High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 122(2), 605–7.
- Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer
  Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., Ford, J. M., … Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER. CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL: JOHN WILEY & SONS INC.
- Novel Treatment Approaches for Triple-Negative Breast Cancer
  Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16–E22.
- Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation
  Matsukuma, K. E., Mullins, F. M., Dietz, L., Zehnder, J. L., Ford, J. M., Chun, N. M., & Schrijver, I. (2010). Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. HUMAN PATHOLOGY, 41(8), 1200–1203.
- Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma
  Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., Kunz, P., … Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER. CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL: WILEY-BLACKWELL.
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
  Hastak, K., Alli, E., & Ford, J. M. (2010). Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin. CANCER RESEARCH, 70(20), 7970–80.
- Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
  Anders, C. K., Winer, E. P., Ford, J. M., Dent, R., Silver, D. P., Sledge, G. W., & Carey, L. A. (2010). Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 16(19), 4702–10.
- Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers
  Schrader, K. A., Masciari, S., Boyd, N., Salamanca, C., Senz, J., Saunders, D. N., … Huntsman, D. G. (2011). Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. JOURNAL OF MEDICAL GENETICS, 48(1), 64–68.
- Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
  Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. A., Lichtensztajn, D., … Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471–78.
- PARP inhibitors in breast cancer.
  Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical Advances in Hematology & Oncology : H&O, 8(9), 629–35.
- Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
  Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., Fisher, G. A., … Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342–51.
- A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer
  Kwong, A., Ng, E. K. O., Tang, E. Y. H., Wong, C. L. P., Law, F. B. F., Leung, C. P. H., … Ford, J. M. (2011). A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. FAMILIAL CANCER, 10(2), 233–37.
- A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer
  Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., Jeffrey, R. B., … Norton, J. A. (2011). A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. ANNALS OF SURGICAL ONCOLOGY, 18(9), 2594–98.
- A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas
  Mojtahed, A., Schrijver, I., Ford, J. M., Longacre, T. A., & Pai, R. K. (2011). A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. MODERN PATHOLOGY, 24(7), 1004–14.
- SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
  Schellenberg, D., Kim, J., Ciristman-Skieller, C., Chun, C. L., Columbo, L. A., Ford, J. M., … Koong, A. C. (2011). SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(1), 181–88.
- HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
  Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., Balise, R. R., … Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13–24.
- Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis
  Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., … Phillips, K. A. (2011). Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis. ANNALS OF INTERNAL MEDICINE, 155(2), 69–U50.
- Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
  Alli, E., Sharma, V. B., Hartman, A.-R., Lin, P. S., McPherson, L., & Ford, J. M. (2011). Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacology, 11, 7-?
- BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS
  Benz, C. C., Keniry, M. A., Ford, J. M., Townsend, A. J., COX, F. W., PALAYOOR, S., … COWAN, K. H. (1990). BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS. MOLECULAR PHARMACOLOGY, 37(6), 840–847.
- PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER
  Ford, J. M., & Hait, W. N. (1990). PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER. PHARMACOLOGICAL REVIEWS, 42(3), 155–199.
- Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
  Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., Ford, J. M., … Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL,IL: ELSEVIER SCIENCE INC.
- Family History As a Positive Prognostic Factor in Gastric Cancer
  Nadauld, L. D., & Ford, J. M. (2012). Family History As a Positive Prognostic Factor in Gastric Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(7), 683–84.
- Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort
  Kwong, A., Wong, C. H. N., Suen, D. T. K., Co, M., Kurian, A. W., West, D. W., & Ford, J. M. (2012). Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. WORLD JOURNAL OF SURGERY, 36(4), 702–13.
- A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male.
  Wanta, S. M., Basina, M., Chang, S. D., Chang, D. T., Ford, J. M., Greco, R., … Kunz, P. L. (2011). A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors, 3(4).
- Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
  Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., … Garber, J. E. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1125–30.
- Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
  Alli, E., & Ford, J. M. (2012). Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA REPAIR, 11(5), 522–24.
- Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
  Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., Jayachandran, P., … Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128–39.
- Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
  Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).
- Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
  de Bruin, M. A., Kwong, A., Goldstein, B. A., Lipson, J. A., Ikeda, D. M., McPherson, L., … Kurian, A. W. (2012). Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. FAMILIAL CANCER, 11(3), 429–39.
- PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
  Vinayak, S., & Ford, J. M. (2010). PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Current Breast Cancer Reports, 2(4), 190–97.
- Genetic Testing by Cancer Site Stomach
  Chun, N., & Ford, J. M. (2012). Genetic Testing by Cancer Site Stomach. CANCER JOURNAL, 18(4), 355–63.
- Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
  Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., … Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939–42.
- Is breast cancer a part of Lynch syndrome?
  Ford, J. M. (2012). Is breast cancer a part of Lynch syndrome? Breast Cancer Research : BCR, 14(4), 110.
- Long-Term Survivors of Gastric Cancer: A California Population-Based Study
  Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507–15.
- Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis
  Kwong, A., Ng, E. K. O., Wong, C. L. P., Law, F. B. F., Au, T., Wong, H. N., … Ma, E. S. K. (2012). Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLOS ONE, 7(9).
- Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene.
  Hastak, K., Adimoolam, S., Trinklein, N. D., Myers, R. M., & Ford, J. M. (2012). Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. Genes & Cancer, 3(2), 131–40.
- Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack
  Ladabaum, U., & Ford, J. M. (2012). Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 308(15), 1581–83.
- Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients
  Kwong, A., Ng, E. K. O., Law, F. B. F., Wong, H. N., Wa, A., Wong, C. L. P., … Ma, E. S. K. (2012). Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 931–33.
- Lupus Antibody Tops Cancer Cells
  Ford, J. M. (2012). Lupus Antibody Tops Cancer Cells. SCIENCE TRANSLATIONAL MEDICINE, 4(157).
- Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
  Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., Kunz, P. L., … Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631–38.
- Molecular profiling of gastric cancer: toward personalized cancer medicine.
  Nadauld, L. D., & Ford, J. M. (2013). Molecular profiling of gastric cancer: toward personalized cancer medicine. Journal of Clinical Oncology , 31(7), 838–39.
- A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.
  de Bruin, M. A., Ford, J. M., & Kurian, A. W. (2013). A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. Journal of the National Comprehensive Cancer Network , 11(5), 512–17.
- Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype.
  Ji, H. P., Morales, S., Welch, K., Yuen, C., Farnam, K., & Ford, J. M. (2012). Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype. BioDiscovery, (1).
- Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR.
  Nadauld, L., Regan, J. F., Miotke, L., Pai, R. K., Longacre, T. A., Kwok, S. S., … Ji, H. P. (2012). Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Translational Medicine (Sunnyvale, Calif.), 2(2).
- TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE
  DeGregorio, M. W., Ford, J. M., Benz, C. C., & Wiebe, V. J. (1989). TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 7(9), 1359–1364.
- STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE
  Ford, J. M., Prozialeck, W. C., & Hait, W. N. (1989). STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE. MOLECULAR PHARMACOLOGY, 35(1), 105–115.
- LI-FRAUMENI SYNDROME FIBROBLASTS HOMOZYGOUS FOR P53 MUTATIONS ARE DEFICIENT IN GLOBAL DNA-REPAIR BUT EXHIBIT NORMAL TRANSCRIPTION-COUPLED REPAIR AND ENHANCED UV RESISTANCE
  Ford, J. M., & Hanawalt, P. C. (1995). LI-FRAUMENI SYNDROME FIBROBLASTS HOMOZYGOUS FOR P53 MUTATIONS ARE DEFICIENT IN GLOBAL DNA-REPAIR BUT EXHIBIT NORMAL TRANSCRIPTION-COUPLED REPAIR AND ENHANCED UV RESISTANCE. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 92(19), 8876–80.
- MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES
  Ford, J. M. (1995). MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 337–61.
- PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE
  Ford, J. M., & Hait, W. N. (1993). PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE. CYTOTECHNOLOGY, 12(1-3), 171–212.
- PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE
  Ford, J. M., Lommel, L., & Hanawalt, P. C. (1994). PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE. MOLECULAR CARCINOGENESIS, 10(2), 105–9.
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
  Ford, J. M. (1996). Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. EUROPEAN JOURNAL OF CANCER, 32A(6), 991–1001.
- P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal.
  Ford, J. M., Yang, J. M., & Hait, W. N. (1996). P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treatment and Research, 87, 3–38.
- Role of DNA excision repair gene defects in the etiology of cancer
  Ford, J. M., & Hanawalt, P. C. (1997). Role of DNA excision repair gene defects in the etiology of cancer. GENETIC INSTABILITY AND TUMORIGENESIS, 221, 47–70.
- Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts
  Ford, J. M., & Hanawalt, P. C. (1997). Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. JOURNAL OF BIOLOGICAL CHEMISTRY, 272(44), 28073–80.
- Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation
  Ford, J. M., Baron, E. L., & Hanawalt, P. C. (1998). Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. CANCER RESEARCH, 58(4), 599–603.
- Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes
  Prost, S., Ford, J. M., Taylor, G., Doig, J., & Harrison, D. J. (1998). Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. JOURNAL OF BIOLOGICAL CHEMISTRY, 273(50), 33327–32.
- Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair
  Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (1999). Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 96(2), 424–28.
- Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium
  Mai, P. L., Malkin, D., Garber, J. E., Schiffman, J. D., Weitzel, J. N., Strong, L. C., … Savage, S. A. (2012). Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. CANCER GENETICS, 205(10), 479–87.
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
  Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., … Bottaro, D. P. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE, 8(3).
- Pathological response after chemoradiation for T3 rectal cancer
  Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24–E30.
- Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
  Bazan, J. G., Hara, W., Kunz, P., Fisher, G. A., Ford, J. M., Welton, M. L., … Chang, D. T. (2010). Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S300–S301.
- Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
  Jhawer, M. P., Kindler, H. L., Wainberg, Z. A., Hecht, J. R., Kerr, R. O., Ford, J. M., … Shah, M. A. (2008). Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
- Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation
  Vossler, S. R., Bavan, B., Kunz, P., Ford, J. M., Fisher, G. A., Whyte, R., … Chang, D. T. (2011). Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S309–S309.
- Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
  Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association , 20(6), 1059–66.
- A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
  Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, E., McPherson, L., … Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Research and Treatment, 142(2), 389–98.
- Colorectal Cancer Screening Clinical Practice Guidelines in Oncology
  Burt, R. W., Cannon, J. A., David, D. S., Early, D. S., Ford, J. M., Giardiello, F. M., … Freedman-Cass, D. (2013). Colorectal Cancer Screening Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(12), 1538–75.
- Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.
  Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer. AMIA Summits on Translational Science Proceedings AMIA Summit on Translational Science, 2013, 62-?
- Clinical interpretation and implications of whole-genome sequencing.
  Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., … Quertermous, T. (2014). Clinical interpretation and implications of whole-genome sequencing. JAMA, 311(10), 1035–45.
- American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
  Lu, K. H., Wood, M. E., Daniels, M., Burke, C., Ford, J., Kauff, N. D., … Hughes, K. S. (2014). American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. Journal of Clinical Oncology , 32(8), 833–40.
- Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
  Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., … Ford, J. M. (2014). Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. JOURNAL OF CLINICAL ONCOLOGY, 32(19), 2001–9.
- The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype.
  Kwok, C.-T., Vogelaar, I. P., van Zelst-Stams, W. A., Mensenkamp, A. R., Ligtenberg, M. J., Rapkins, R. W., … Hitchins, M. P. (2014). The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. European Journal of Human Genetics , 22(5), 617–24.
- Clinical interpretation and implications of whole-genome sequencing.
  Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., … Quertermous, T. (2014). Clinical interpretation and implications of whole-genome sequencing. JAMA : the Journal of the American Medical Association, 311(10), 1035–45.
- American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers.
  Lu, K. H., Wood, M. E., Daniels, M., Burke, C., Ford, J., Kauff, N. D., … Hughes, K. S. (2014). American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers. Journal of Clinical Oncology , 32(8), 833–40.
- Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.
  Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J. M., Miotke, L., Hopmans, E. S., … Ji, H. P. (2014). Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biology, 15(8), 428-?
- Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer
  Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., & Longacre, T. A. (2014). Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 38(11), 1501–9.
- Parent Decision-Making Around the Genetic Testing of Children for Germline TP53 Mutations
  Alderfer, M. A., Zelley, K., Lindell, R. B., Novokmet, A., Mai, P. L., Garber, J. E., … Nichols, K. E. (2015). Parent Decision-Making Around the Genetic Testing of Children for Germline TP53 Mutations. CANCER, 121(2), 286–93.
- Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
  McPherson, L. A., Shen, Y., & Ford, J. M. (2014). Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. CANCER LETTERS, 343(2), 217–23.
- Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.
  Kurian, A. W., Kingham, K. E., & Ford, J. M. (2015). Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Current Opinion in Obstetrics & Gynecology, 27(1), 23–33.
- Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
  Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(4), 918–25.
- Therapeutic Targeting of BRCA1-Mutated Breast Cancers with Agents That Activate DNA Repair
  Alli, E., Solow-Cordero, D., Casey, S. C., & Ford, J. M. (2014). Therapeutic Targeting of BRCA1-Mutated Breast Cancers with Agents That Activate DNA Repair. CANCER RESEARCH, 74(21), 6205–15.
- Multigene Panel Testing in Oncology Practice: How Should We Respond?
  Kurian, A. W., & Ford, J. M. (2015). Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncology, 1(3).
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology , 33(17), 1895–1901.
- Multiple-Gene Panels and the Future of Genetic Testing
  Kurian, A. W., & Ford, J. M. (2015). Multiple-Gene Panels and the Future of Genetic Testing. Current Breast Cancer Reports.
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
  Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., … Tutt, A. N. J. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. CANCER DISCOVERY, 5(5), 488–505.
- Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation.
  Mahmud, N., Ford, J. M., Longacre, T. A., Parent, R., & Norton, J. A. (2015). Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation. Journal of Clinical Oncology , 33(4), e19–21.
- NCCN clinical practice guidelines in oncology. Colorectal cancer screening.
  Burt, R. W., Barthel, J. S., Dunn, K. B., David, D. S., Drelichman, E., Ford, J. M., … Weinberg, D. (2010). NCCN clinical practice guidelines in oncology. Colorectal cancer screening. Journal of the National Comprehensive Cancer Network , 8(1), 8–61.
- BRCA1: Beyond double-strand break repair
  Alli, E., & Ford, J. M. (2015). BRCA1: Beyond double-strand break repair. DNA REPAIR, 32, 165–71.
- Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
  van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., … Fitzgerald, R. C. (2015). Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. JOURNAL OF MEDICAL GENETICS, 52(6), 361–74.
- Multigene Panel Testing in Oncology Practice: How Should We Respond?
  Kurian, A. W., & Ford, J. M. (2015). Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncology, 1(3), 277–78.
- Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries
  Kwong, A., Shin, V. Y., Ho, J. C. W., Kang, E., Nakamura, S., Teo, S.-H., … Kim, S.-W. (2016). Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. JOURNAL OF MEDICAL GENETICS, 53(1), 15–23.
- A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients
  Lincoln, S. E., Kobayashi, Y., Anderson, M. J., Yang, S., Desmond, A. J., Mills, M. A., … Ellisen, L. W. (2015). A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. JOURNAL OF MOLECULAR DIAGNOSTICS, 17(5), 533–44.
- Colorectal cancer screening.
  Burt, R. W., Cannon, J. A., David, D. S., Early, D. S., Ford, J. M., Giardiello, F. M., … Freedman-Cass, D. (2013). Colorectal cancer screening. Journal of the National Comprehensive Cancer Network , 11(12), 1538–1575.
- Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
  Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., … Ellisen, L. W. (2015). Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 1(7), 943–51.
- Colorectal Cancer Screening, Version 1.2015 Featured Updates to the NCCN Guidelines
  Provenzale, D., Jasperson, K., Ahnen, D. J., Aslanian, H., Bray, T., Cannon, J. A., … Darlow, S. (2015). Colorectal Cancer Screening, Version 1.2015 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(8), 959–68.
- American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome
  Ladabaum, U., Ford, J. M., Martel, M., & Barkun, A. N. (2015). American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. GASTROENTEROLOGY, 149(3), 783-?
- Metastatic Lobular Breast Carcinoma Mimicking Primary Signet Ring Adenocarcinoma in a Patient With a Suspected CDH1 Mutation
  Mahmud, N., Ford, J. M., Longacre, T. A., Parent, R., & Norton, J. A. (2015). Metastatic Lobular Breast Carcinoma Mimicking Primary Signet Ring Adenocarcinoma in a Patient With a Suspected CDH1 Mutation. JOURNAL OF CLINICAL ONCOLOGY, 33(4), E19–E21.
- Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer
  Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J. M., Miotke, L., Hopmans, E. S., … Ji, H. P. (2014). Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. GENOME BIOLOGY, 15(8).
- Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.
  Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. International Journal of Radiation Oncology, Biology, Physics, 90(4), 918–25.
- American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome.
  Ladabaum, U., Ford, J. M., Martel, M., & Barkun, A. N. (2015). American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. Gastroenterology, 149(3), 783–813 e20.
- Colorectal Cancer Screening, Version 1.2015.
  Provenzale, D., Jasperson, K., Ahnen, D. J., Aslanian, H., Bray, T., Cannon, J. A., … Darlow, S. (2015). Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network , 13(8), 959–68.
- Discovery and functional characterization of a neomorphic PTEN mutation
  Costa, H. A., Leitner, M. G., Sos, M. L., Mavrantoni, A., Rychkova, A., Johnson, J. R., … Bustamante, C. D. (2015). Discovery and functional characterization of a neomorphic PTEN mutation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 112(45), 13976–81.
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
  Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., … Lindor, N. M. (2015). American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology , 33(31), 3660–67.
- The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer
  Kwong, A., Chen, J., Shin, V. Y., Ho, J. C. W., Law, F. B. F., Au, C. H., … Ford, J. M. (2015). The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. CANCER GENETICS, 208(9), 448–54.
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
  Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., … Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research , 22(15), 3764–73.
- DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications
  Liu, I. H., Ford, J. M., & Kunz, P. L. (2016). DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. CANCER TREATMENT REVIEWS, 44, 1–9.
- DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
  Liu, I. H., Ford, J. M., & Kunz, P. L. (2016). DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews, 44, 1–9.
- BRCA1: a movement toward cancer prevention.
  Alli, E., & Ford, J. M. (2015). BRCA1: a movement toward cancer prevention. Molecular & Cellular Oncology, 2(3).
- Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel
  Kwong, A., Shin, V. Y., Au, C. H., Law, F. B. F., Ho, D. N., Ip, B. K., … Chan, T. L. (2016). Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. JOURNAL OF MOLECULAR DIAGNOSTICS, 18(4), 580–94.
- A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target.
  Ji, D., Beharry, A. A., Ford, J. M., & Kool, E. T. (2016). A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. Journal of the American Chemical Society, 138(29), 9005–8.
- Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): Pathologic findings with clinical implications
  Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., Huntsman, D. G., … Longacre, T. A. (2008). Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): Pathologic findings with clinical implications. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 32A(6), 799–809.
- Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
  Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., … Telli, M. L. (2017). Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016
  Provenzale, D., Gupta, S., Ahnen, D. J., Bray, T., Cannon, J. A., Cooper, G., … Darlow, S. (2016). Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(8), 1010–30.
- A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
  Haslem, D. S., Van Norman, S. B., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., … Nadauld, L. D. (2016). A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. Journal of Oncology Practice.
- Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment
  Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., … Ellisen, L. (2015). Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA ONCOLOGY, 1(7), 943–51.
- Genetic predisposition to gastric cancer
  Petrovchich, I., & Ford, J. M. (2016). Genetic predisposition to gastric cancer. SEMINARS IN ONCOLOGY, 43(5), 554–59.
- Long-read genome sequencing identifies causal structural variation in a Mendelian disease.
  Merker, J. D., Wenger, A. M., Sneddon, T., Grove, M., Zappala, Z., Fresard, L., … Ashley, E. A. (2017). Long-read genome sequencing identifies causal structural variation in a Mendelian disease. Genetics in Medicine : Official Journal of the American College of Medical Genetics.
- Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
  Hastak, K., Bhutra, S., Parry, R., & Ford, J. M. (2017). Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. ONCOTARGET, 8(16), 26344–55.
- Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
  Caswell-Jin, J. L., Gupta, T., Hall, E., Petrovchich, I. M., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2017). Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine : Official Journal of the American College of Medical Genetics.
- Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.
  Greer, S. U., Nadauld, L. D., Lau, B. T., Chen, J., Wood-Bouwens, C., Ford, J. M., … Ji, H. P. (2017). Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Medicine, 9(1), 57.
- IDH2 Mutation in a Patient with Metastatic Colon Cancer
  Zhang, B. M., Zehnder, J. L., & Suarez, C. J. (2017). IDH2 Mutation in a Patient with Metastatic Colon Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 376(20), 1991–92.
- Patient communication of cancer genetic test results in a diverse population.
  Ricker, C. N., Koff, R. B., Qu, C., Culver, J., Sturgeon, D., Kingham, K. E., … Idos, G. E. (2018). Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 8(1), 85–94.
- Rapid detection ofBRCA1/2recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
  Kwong, A., Ho, J. C., Shin, V. Y., Kurian, A. W., Tai, E., Esserman, L. J., … Ford, J. M. (2018). Rapid detection ofBRCA1/2recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 9(8), 7832–43.
- Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
  Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC
  Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., … Telli, M. L. (2015). Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy
  Lei, L., Lin, C.-Y., Steiner, D., Ford, J. M., Zehnder, J. L., & Suarez, C. J. (2018). Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
  Telli, M. L., Hellyer, J., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., … Ford, J. M. (2018). Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Research and Treatment, 168(3), 625–30.
- Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
  Doherty, M. R., Cheon, H. J., Junk, D. J., Vinayak, S., Varadan, V., Telli, M. L., … Jackson, M. W. (2017). Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 114(52), 13792–97.
- The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (vol 3, 22, 2017)
  Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., … Couch, F. J. (2017). The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (vol 3, 22, 2017). NPJ BREAST CANCER, 3, 44.
- NCCN Guidelines (R) Insights Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017 Featured Updates to the NCCN Guidelines
  Gupta, S., Provenzale, D., Regenbogen, S. E., Hampel, H., Slavin, T. P., Hall, M. J., … Ogba, N. (2017). NCCN Guidelines (R) Insights Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(12), 1465–74.
- Lynch Syndrome Screening: Discordance in MMR and Germline Test Results
  Mafnas, C., Martin, B., Ford, J., & Longacre, T. (2015). Lynch Syndrome Screening: Discordance in MMR and Germline Test Results. MODERN PATHOLOGY, 28, 177A.
- Lynch Syndrome Screening: Discordance in MMR and Germline Test Results
  Mafnas, C., Martin, B., Ford, J., & Longacre, T. (2015). Lynch Syndrome Screening: Discordance in MMR and Germline Test Results. LABORATORY INVESTIGATION, 95, 177A.
- Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.
  Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies.
- NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
  Provenzale, D., Gupta, S., Ahnen, D. J., Markowitz, A. J., Chung, D. C., Mayer, R. J., … Ogba, N. (2018). NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal of the National Comprehensive Cancer Network : JNCCN, 16(8), 939–49.
- ASSOCIATION OF 7Q34 COPY NUMBER GAINS AND KIAA1549-BRAF GENE FUSIONS WITH JUVENILE PILOCYTIC ASTROCYTOMA
  Hodgson, J. G., VandenBerg, S. R., James, C. D., Perry, A., Gutmann, D., Fisher, P., … Schiffman, J. (2009). ASSOCIATION OF 7Q34 COPY NUMBER GAINS AND KIAA1549-BRAF GENE FUSIONS WITH JUVENILE PILOCYTIC ASTROCYTOMA. NEURO-ONCOLOGY, 11(6), 960.
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing
  Trosman, J. R., Weldon, C. B., Gradishar, W. J., Benson, A. B., Cristofanilli, M., Kurian, A. W., … Phillips, K. A. (2018). From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health, 1062–68.
- Small molecules facilitating DNA repair in breast cancer cells
  Pandrala, M., Hastak, K., Kumar, V., Gardiner, M., Ford, J., & Malhotra, S. (2018). Small molecules facilitating DNA repair in breast cancer cells. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 256.
- Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?
  Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing? JCO Precision Oncology.
- Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy
  Lei, L., Lin, C.-Y., Steiner, D., Ford, J. M., Zehnder, J. L., & Suarez, C. J. (2018). Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations - Reply
  Norton, J. A., & Ford, J. M. (2008). Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations - Reply. ANNALS OF SURGERY, 247(4), 715–16.
- Molecular receptor profiles in male mutation carriers with breast cancer
  Wapnir, I., Kingham, K., Mills, M., Ford, J., & Kurian, A. (2017). Molecular receptor profiles in male mutation carriers with breast cancer. ANNALS OF SURGICAL ONCOLOGY, 24, 112–13.
- Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.
  Haslem, D. S., Chakravarty, I., Fulde, G., Gilbert, H., Tudor, B. P., Lin, K., … Nadauld, L. D. (2018). Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget, 9(15), 12316–22.
- The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
  Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., … Couch, F. J. (2017). The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ BREAST CANCER, 3, 22.
- Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage
  Alli, E., & Ford, J. M. (2012). Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage. CANCER RESEARCH, 72.
- Precision genomic medicine improves clinical outcomes in advanced cancer patients
  Nadauld, L. D., Van Norman, B., Fulde, G., Newman, D., Butler, A., Tudor, B., … Haslem, D. (2016). Precision genomic medicine improves clinical outcomes in advanced cancer patients. CLINICAL CANCER RESEARCH, 22.
- Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.
  Vinayak, S., Gray, R. J., Adams, S., Jensen, K. C., Manola, J., Afghahi, A., … Telli, M. L. (2014). Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Hereditary Gastric Cancer An Update at 15 Years
  Ford, J. M. (2015). Hereditary Gastric Cancer An Update at 15 Years. JAMA ONCOLOGY, 1(1), 16–18.
- DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications
  Liu, I. H., Ford, J. M., & Kunz, P. L. (2015). DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications. PANCREAS, 44(2), 355.
- Male Breast Cancer: A Comparison Between BRCA Mutation Carriers and Noncarriers in Hong Kong, Southern China
  Kwong, A., Chau, W. W., Law, F. B. F., Kurian, A., Ford, J. M., West, D. W., & Ma, E. S. K. (2013). Male Breast Cancer: A Comparison Between BRCA Mutation Carriers and Noncarriers in Hong Kong, Southern China. ANNALS OF SURGICAL ONCOLOGY, 20, 72.
- Tailoring BRCAPRO to Asian-Americans IN REPLY
  Kurian, A. W., Whittemore, A. S., & Ford, J. M. (2009). Tailoring BRCAPRO to Asian-Americans IN REPLY. JOURNAL OF CLINICAL ONCOLOGY, 27(4), 643–44.
- Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
  Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., … Mukherjee, B. (2019). Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology.
- Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies
  Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., … Suarez, C. J. (2018). Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. JCO PRECISION ONCOLOGY, 2.
- Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study
  Powell, S. E., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M., Hack, K. M., … Gaba, A. G. (2018). Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO PRECISION ONCOLOGY, 2, 1–12.
- Precision Oncology: A New Forum for an Emerging Field
  Ford, J. M. (2017). Precision Oncology: A New Forum for an Emerging Field. JCO PRECISION ONCOLOGY, 1.
- Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series
  Ford, J. M. (2018). Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series. JCO PRECISION ONCOLOGY, 2.
- Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
  Haslem, D. S., Ji, H. P., Ford, J. M., & Nadauld, L. D. (2017). Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO PRECISION ONCOLOGY, 1.
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.
  Trosman, J. R., Weldon, C. B., Gradishar, W. J., Benson, A. B., Cristofanilli, M., Kurian, A. W., … Phillips, K. A. (2018). From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 21(9), 1062–1068.
- Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst
  Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. COLD SPRING HARBOR MOLECULAR CASE STUDIES, 4(5).
- Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions
  Nadauld, L. D., Ford, J. M., Pritchard, D., & Brown, T. (2018). Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions. HEALTH AFFAIRS, 37(5), 751–56.
- Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations
  Tsang, A., Kingham, K., Kurian, A., Ford, J., & Wapnir, I. (2019). Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
  Chen, J., Haanpää, M. K., Gruber, J. J., Jäger, N., Ford, J. M., & Snyder, M. P. (2019). High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
  Lal, A., Ramazzotti, D., Weng, Z., Liu, K., Ford, J. M., & Sidow, A. (2019). Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. BMC Medical Genomics, 12(1), 84.
- Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
  Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 24(12), 2851–58.
- VISTA immune checkpoint deregulation in human triple-negative breast cancer
  Gruber, J. J., Juntilla, M. M., Yang, S.-R., Geller, B., Jager, N., Lin, C.-Y., … Snyder, M. P. (2018). VISTA immune checkpoint deregulation in human triple-negative breast cancer. CANCER RESEARCH, 78(13).
- HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding.
  Gruber, J. J., Geller, B., Lipchik, A. M., Chen, J., Salahudeen, A. A., Ram, A. N., … Snyder, M. P. (2019). HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding. Molecular Cell.
- Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.
  McPherson, L. A., Troccoli, C. I., Ji, D., Bowles, A. E., Gardiner, M. L., Mohsen, M. G., … Ford, J. M. (2019). Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. DNA Repair, 102644.
- Chromatin Remodeling in Response to BRCA2-Crisis.
  Gruber, J. J., Chen, J., Geller, B., Jäger, N., Lipchik, A. M., Wang, G., … Snyder, M. P. (2019). Chromatin Remodeling in Response to BRCA2-Crisis. Cell Reports, 28(8), 2182–93.e6.
- Genomics in medicine: a novel elective rotation for internal medicine residents.
  Geng, L. N., Kohler, J. N., Levonian, P., Bernstein, J. A., Ford, J. M., Ahuja, N., … Wheeler, M. (2019). Genomics in medicine: a novel elective rotation for internal medicine residents. Postgraduate Medical Journal.
- Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
  Gruber, J. J., Afghahi, A., Hatton, A., Scott, D., McMillan, A., Ford, J. M., & Telli, M. L. (2019). Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
  Hyman, D. M., Zelnak, A. B., Bauer, T. M., Ulahannan, S. V., Ford, J. M., Cesari, R., … Yap, T. A. (2019). JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Preventive surgery after multiplex genetic panel testing (MGPT)
  Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., … Gruber, S. B. (2019). Preventive surgery after multiplex genetic panel testing (MGPT). JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- NCI-MATCH EAY131-Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations
  Kummar, S., Li, S., Reiss, K., Ford, J. M., Mitchell, E. P., Zwiebel, J. A., … Flaherty, K. T. (2019). NCI-MATCH EAY131-Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.
  Shukla, N., Abrha, A., Longacre, T. A., Koff, R., Ford, J. M., Fisher, G. A., & Haraldsdottir, S. (2019). Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(4).
- Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
  Telli, M. L., Chu, C., Badve, S. S., Vinayak, S., Silver, D. P., Isakoff, S. J., … Richardson, A. L. (2019). Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Statistical Methods in Precision Oncology.
  Lu, Y., Lee, J. J., & Ford, J. M. (2020). Statistical Methods in Precision Oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1903173.
- Germline mutation in 1,338 BRCA-negative Chinese hereditary breast and/or ovarian cancer patients: clinical testing with a multigene test panel.
  Kwong, A., Shin, V. Y., Chen, J., Wai-Yin Cheuk, I., Ho, C. Y., Au, C. H., … Ma, E. S. (2020). Germline mutation in 1,338 BRCA-negative Chinese hereditary breast and/or ovarian cancer patients: clinical testing with a multigene test panel. The Journal of Molecular Diagnostics : JMD.
- Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer.
  Xia, L. C., Van Hummelen, P., Kubit, M., Lee, H. J., Bell, J. M., Grimes, S. M., … Nadauld, L. D. (2020). Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. Scientific Reports, 10(1), 5009.
- Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing
  Vlessis, K., Purington, N., Chun, N., Haraldsdottir, S., & Ford, J. M. (2020). Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing. JNCI CANCER SPECTRUM, 4(1), pkz095.
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
  Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., … Williams, E. H. (2020). The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 181(2), 236–49.
- One Step Further Toward Defining the Exceptional Cancer Responder.
  Ford, J. M., & Mitchell, B. S. (2020). One Step Further Toward Defining the Exceptional Cancer Responder. Journal of the National Cancer Institute.
- Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer
  Almeda, A. F., Hooker, A., Lee, H., Mills, M., Van Hummelen, P., Ford, J. M., & Ji, H. (2020). Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(4).
- Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling
  Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., … Gruber, S. B. (2018). Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
- Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling
  Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., … Gruber, S. B. (2018). Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
- Hereditary diffuse gastric cancer: updated clinical practice guidelines
  Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., Dieren, J. M. van, … Guilford, P. (2020). Hereditary diffuse gastric cancer: updated clinical practice guidelines. LANCET ONCOLOGY, 21(8), E386–E397.
- Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.
  Haslem, D. S., Ji, H. P., Ford, J. M., & Nadauld, L. D. (2017). Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 1.
- Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.
  Maxwell, K. N., Wenz, B. M., Kulkarni, A., Wubbenhorst, B., D'Andrea, K., Weathers, B., … Nathanson, K. L. (2020). Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 4.
- Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.
  Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., … Telli, M. L. (2020). Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
- A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma
  Chen, L., Bellone, R. R., Wang, Y., Singer-Berk, M., Sugasawa, K., Ford, J. M., & Artandi, S. E. (2020). A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. DNA Repair.
- Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.
  Abrha, A., Shukla, N. D., Hodan, R., Longacre, T., Raghavan, S., Pritchard, C. C., … Haraldsdottir, S. (2020). Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. JNCI Cancer Spectrum, 4(5), pkaa054.
- A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.
  Chen, L., Bellone, R. R., Wang, Y., Singer-Berk, M., Sugasawa, K., Ford, J. M., & Artandi, S. E. (2020). A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. DNA Repair, 97, 103022.
- Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
  Culver, J. O., Ricker, C. N., Bonner, J., Kidd, J., Sturgeon, D., Hodan, R., … Idos, G. E. (2020). Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer.
- Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
  Hodan, R., Kingham, K., Cotter, K., Folkins, A. K., Kurian, A. W., Ford, J. M., & Longacre, T. (2020). Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. Cancer Medicine.
- Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
  Lim, J. K., Chang, A. Y., Zaman, A., Martin, P., Fernandez-Rodriguez, C. M., Korkmaz, M., … Colombato, L. (2020). Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Journal of Clinical and Translational Hepatology, 8(4), 377–84.
- Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations
  Gruber, J. J., Afghahi, A., Hatton, A., Gross, W., Foran, J., McMillan, A., … Telli, M. L. (2021). Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations. CANCER RESEARCH, 81(4).
- Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.
  Harding, J. J., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., … Abou-Alfa, G. K. (2021). Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.
  Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., … Gruber, S. B. (2019). Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology, 3.
- Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations.
  Ladabaum, U., Ford, J. M., Poultsides, G., & Norton, J. (2021). Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations. Gastrointestinal Endoscopy.
- Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies.
  Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., … Suarez, C. J. (2018). Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. JCO Precision Oncology, 2, 1–4.
- Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
  Krop, I. E., Jegede, O. A., Grilley-Olson, J. E., Lauring, J. D., Mitchell, E. P., Zwiebel, J. A., … Flaherty, K. T. (2022). Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precision Oncology, 6, e2100424.
- Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
  Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? JCO Precision Oncology, 2, 1–10.
- Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.
  Powell, S. F., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M., Hack, K. M., … Gaba, A. G. (2018). Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO Precision Oncology, 2, 1–12.
- Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series.
  Ford, J. M. (2018). Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series. JCO Precision Oncology, 2, 1.
- Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.
  Forrester, J. D., Foster, D., Ford, J. M., Longacre, T. A., Ladabaum, U., Fry, S., & Norton, J. A. (2022). Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes. Cancers, 14(3).
- Precision Oncology: A New Forum for an Emerging Field.
  Ford, J. M. (2017). Precision Oncology: A New Forum for an Emerging Field. JCO Precision Oncology, 1, 1–2.
- Totally Unexpected: Nonsyndromic CDH1 Mutations and Hereditary Diffuse Gastric Cancer Syndrome.
  Ford, J. M. (2017). Totally Unexpected: Nonsyndromic CDH1 Mutations and Hereditary Diffuse Gastric Cancer Syndrome. JCO Precision Oncology, 1, 1–2.
- MITI minimum information guidelines for highly multiplexed tissue images.
  Schapiro, D., Yapp, C., Sokolov, A., Reynolds, S. M., Chen, Y.-A., Sudar, D., … Sorger, P. K. (2022). MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 19(3), 262–267.
- Somatic tumor testing implications for Lynch syndrome germline genetic testing.
  Barrus, K., Purington, N., Chun, N., Ladabaum, U., & Ford, J. M. (2022). Somatic tumor testing implications for Lynch syndrome germline genetic testing. Cancer Genetics, 264-265, 16–22.
- A Novel Framework for the Next Generation of Precision Oncology Targets.
  Chen, C. T., & Ford, J. M. (2022). A Novel Framework for the Next Generation of Precision Oncology Targets. JAMA Oncology.
- Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
  Archer, S., Fennell, N., Colvin, E., Laquindanum, R., Mills, M., Dennis, R., … Tischkowitz, M. (2022). Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 14(11).
- Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer.
  Becker, W. R., Nevins, S. A., Chen, D. C., Chiu, R., Horning, A. M., Guha, T. K., … Greenleaf, W. J. (2022). Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nature Genetics.
- The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer.
  Almeda, A. F., Grimes, S. M., Lee, H. J., Greer, S., Shin, G. W., McNamara, M., … Ji, H. P. (2022). The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.
- Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1.
  Lee, Y., Onishi, Y., McPherson, L., Kietrys, A. M., Hebenbrock, M., Jun, Y. W., … Kool, E. T. (2022). Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1. ACS Chemical Biology.
- Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
  Rodriguez, C. P., Kang, H., Geiger, J. L., Burtness, B., Chung, C. H., Pickering, C. R., … Malik, S. (2022). Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute.
- Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.
  Llorin, H., Graf, M., Chun, N., & Ford, J. (2022). Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing. Cancer Genetics, 268-269, 22–27.
- Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
  Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., … Ford, J. M. (2022). Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology.
- A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
  Gruber, J. J., Afghahi, A., Timms, K., DeWees, A., Gross, W., Aushev, V. N., … Telli, M. L. (2022). A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer.
- Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
  Harding, J. J., Piha-Paul, S. A., Shah, R. H., Cleary, J. M., Quinn, D. I., Brana, I., … Abou-Alfa, G. K. (2022). Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.
  Timms, K., Lenz, L., Cogan, E. S., Mayer, E. L., Kaklamani, V. G., Stearns, V., … Telli, M. L. (2022). Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
  Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., … Tutt, A. N. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
  Meric-Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., … Moscow, J. A. (2023). National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma.
  King, D. A., Weiel, J. J., Reyes, R., Mills, M., Itchon, A., Fisher, G. A., … Suarez, C. J. (2023). Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma. JCO Precision Oncology, 7, e2200093.
- Identification of a potential chemoprevention agent for BRCA1- mutated cancers.
  Shanmugam, S., Hosch, E., Konar, D., Ford, J. M., & Alli, E. (2022). Identification of a potential chemoprevention agent for BRCA1- mutated cancers. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH.
- Identification of a potential chemoprevention agent for BRCA1- mutated cancers
  Shanmugam, S., Hosch, E., Konar, D., Ford, J. M., & Alli, E. (2022). Identification of a potential chemoprevention agent for BRCA1- mutated cancers. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH.
- Clinical implications of conflicting variant interpretations in the cancer genetics clinic.
  Zukin, E., Culver, J. O., Liu, Y., Yang, Y., Ricker, C. N., Hodan, R., … Idos, G. E. (2023). Clinical implications of conflicting variant interpretations in the cancer genetics clinic. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 100837.
- The New NCI Precision Medicine Trials.
  Harris, L. N., Blanke, C. D., Erba, H. P., Ford, J. M., Gray, R. J., LeBlanc, M. L., … Doroshow, J. H. (2023). The New NCI Precision Medicine Trials. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
  Lenz, L., Neff, C., Solimeno, C., Cogan, E. S., Abramson, V. G., Boughey, J. C., … Timms, K. M. (2023). Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Breast Cancer Research and Treatment.
- Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease.
  Rodrigues, A., Chernikova, S. B., Wang, Y., Trinh, T. T., Solow-Cordero, D. E., Alexandrova, L., … Hayden-Gephart, M. (2024). Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease. Research Square.
- Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
  Rodrigues, A. J., Chernikova, S. B., Wang, Y., Trinh, T. T., Solow-Cordero, D. E., Alexandrova, L., … Hayden-Gephart, M. (2024). Repurposing mebendazole against triple-negative breast cancer CNS metastasis. Journal of Neuro-Oncology.
- Germline CDH1 Variants and Lifetime Cancer Risk.
  Ryan, C. E., Fasaye, G.-A. A., Gallanis, A. F., Gamble, L. A., McClelland, P. H., Duemler, A., … Davis, J. L. (2024). Germline CDH1 Variants and Lifetime Cancer Risk. JAMA.
- Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesis.
  Esplin, E. D., Hanson, C., Wu, S., Horning, A. M., Barapour, N., Nevins, S. A., … Snyder, M. P. (2024). Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesis. Nature Cancer.
- Global loss of promoter-enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis.
  Zhu, Y., Lee, H., White, S., Weimer, A. K., Monte, E., Horning, A., … Snyder, M. P. (2024). Global loss of promoter-enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis. Nature Cancer.

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer

Specializing In

Heritable Disease Genetic Testing
Li-Fraumeni Syndrome
Lynch Syndrome

Practice Locations

GI Cancer Prevention Program in Redwood City Redwood City, CA

Redwood City, CA

GI Cancer Prevention Program in Redwood City

420 Broadway Street, Pavilion D 2nd Floor

Redwood City , CA 94063

(650) 736-5555

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Reviews

(76 reviews)

Helpful and reassuring

Sep 2024

•

Verified SHC Patient

He was very informative regarding my medical condition. Answered all my questions. Enjoyable consult.

Aug 2024

•

Verified SHC Patient

James Fordâ€™s assistant conducted my video interview. His assistant was excellent.

Aug 2024

•

Verified SHC Patient

Both the Dr. and is assistant were terrific. It was a long video visit they were both extremely nice, good explanations of everything discussed. The letter is good for re-enfoced information.

Jul 2024

•

Verified SHC Patient

Very understanding. Provided a wealth of knowledge and expertise. As did Kerry Kingham.

May 2024

•

Verified SHC Patient

VERY NICE, AND VERY APPROACHABLE.

May 2024

•

Verified SHC Patient

He was straight forward with his recommendations.

Mar 2024

•

Verified SHC Patient

My visit with Shilpa Narayan and Dr. Ford was informative and concise.

Nov 2023

•

Verified SHC Patient

He was helpful!

Nov 2023

•

Verified SHC Patient

Heâ€™s very thorough! Explains everything in most simplified terms exact about whatâ€™s going on and so knowledgeable.

Nov 2023

•

Verified SHC Patient

He explained everything well and was very knowledgeable in genetics ..

Nov 2023

•

Verified SHC Patient

Not enough info to comment, but his info and attention to me was good.

Oct 2023

•

Verified SHC Patient

Personable and informative. A great deal of the visit was conducted by a genetic counselor who was also outstanding.

Sep 2023

•

Verified SHC Patient

I am extremely confident that Dr. James Ford, Answers to my questions and concerns were well explain and satisfactory to the end. Thank you.

Aug 2023

•

Verified SHC Patient

Succinct, open, insightful.

Aug 2023

•

Verified SHC Patient

I know his reputation and glad to have him as my doctor.

Aug 2023

•

Verified SHC Patient

The video visit with Dr. Ford seemed like a face to face visit.

Jul 2023

•

Verified SHC Patient

I appreciate his advice and will follow it.

Jun 2023

•

Verified SHC Patient

was self explanatory

May 2023

•

Verified SHC Patient

I'd like to thank both Dr. Ford AND Misha Raskin. Misha took a deep dive into my family's genetics. It's my hope that with the ever evolving genetics field that diseases that can be (mostly) attributed to a person's genetics can be cured by "tweaking" a gene or two. Thank you again Misha and Dr Ford. They both deserve raises!

May 2023

•

Verified SHC Patient

Caring doctor and staff. Listen well and explain things clearly.

Feb 2023

•

Verified SHC Patient

Very great doctor

Dec 2022

•

Verified SHC Patient

Dr. Ford and his colleague answered all my questions and more. I was awed that they had the patience to listen to my poorly worded questions and respond with precise answers that a layman could comprehend.

Dec 2022

•

Verified SHC Patient

Dr. Ford was wonderful confirming the course of testing and the realistic time in receiving the results.

Dec 2022

•

Verified SHC Patient

I thought he was kind, professional and I read his bio prior and its QUITE impressive.

Nov 2022

•

Verified SHC Patient

Great doctor.

Nov 2022

•

Verified SHC Patient

Nice consultation

Nov 2022

•

Verified SHC Patient

Berry good

Sep 2022

•

Verified SHC Patient

He was very clear in his communication of what will be done with the genetic info.

Sep 2022

•

Verified SHC Patient

Very professional, clear with his feedback and questions and explanations!

Sep 2022

•

Verified SHC Patient

Thank you Misha and Dr Fordâ€™s evaluation

Aug 2022

•

Verified SHC Patient

Thank you for taking the time to meet with me today!

Aug 2022

•

Verified SHC Patient

Dr. Ford was good, but the other doctor who gave all the preliminary info and gathered family history was so patient, knowledgeable and enthusiastic even though she must have explained things to so many before me. It was clear that she loves her work and cares about me and my family's multiple challenges with cancer. Continued excellent care from Stanford!

Aug 2022

•

Verified SHC Patient

He is excellent

Aug 2022

•

Verified SHC Patient

Good, informative meeting. Answered all my questions

Jul 2022

•

Verified SHC Patient

I want to thank him for his help. Thank you Dr. Ford!

Jul 2022

•

Verified SHC Patient

He is an excellent doctor. I found him to be extremely knowledgable (an expert in his field) and quite compassionate. I'm grateful for the time I had with him today.

Jul 2022

•

Verified SHC Patient

Well organised meeting. Very informative meeting..

Jul 2022

•

Verified SHC Patient

Dr. Ford answered my questions succinctly.

May 2022

•

Verified SHC Patient

James ford did not join the video visit till we were about 35 minutes into the interview and then while we were talking we signed off . SO I never got to speak with him

May 2022

•

Verified SHC Patient

We had a good visit with Dr. Ford.

Mar 2022

•

Verified SHC Patient

Dr Ford and his team work well together and his team seems well coordinated

Mar 2022

•

Verified SHC Patient

Very informative, kind and inclusive.

Jan 2022

•

Verified SHC Patient

Dr. Ford is an excellent communicator as he explains well very complex medical issues, and encourages patients to ask questions to confirm that they understood.

Nov 2021

•

Verified SHC Patient

Dr. Ford is knowledgeable about my conditions and a good match up with me as a patient. I look forward to getting the most that Stanford may help me with.

Oct 2021

•

Verified SHC Patient

Everything was extremely clear with the video visit

Sep 2021

•

Verified SHC Patient

He approved the plan of action that the staff member and I had agreed to. This exactly what I wanted to occur.

Sep 2021

•

Verified SHC Patient

I appreciate his research very much, and I am grateful for his care

Sep 2021

•

Verified SHC Patient

He was warm, interested in my responses and made me feel engaged in my cancer problem. He answered my questions and gave me additional information. Left me with the belief he can be contacted if necessary.

Sep 2021

•

Verified SHC Patient

Thoughtful, helpful, and willing to listen and provide guidance, as well Megan was communicative, thoughtful, terrific, knowledgeable, and well informed

Aug 2021

•

Verified SHC Patient

short but informative

Aug 2021

•

Verified SHC Patient

Very satisfied with the quality time he spent with me

Jun 2021

•

Verified SHC Patient

My first impression was very good...

Jun 2021

•

Verified SHC Patient

Thank you and your staff for a great visit.

May 2021

•

Verified SHC Patient

Dr. Ford was very impatient during the video visit. He was trying to end the conversation instead of trying to understand more about my issue, even though I was very polite and patient during the whole process. I was disappointed that he was neither helpful nor even trying to be polite. The visit made me uncomfortable.

May 2021

•

Verified SHC Patient

He was great.

Apr 2021

•

Verified SHC Patient

Dr. Ford appeared impatient and lacked empathy. He did not demonstrate much compassion or understanding of how families of other cultures function. I would not recommend him as a doctor.

Dec 2019

•

Verified SHC Patient

My doctor and PA concerns about how I feel. They asked how I'm doing.

Oct 2019

•

Verified SHC Patient

Lots of time w/counselor very brief time w/genetic doctor (5 mins. - 10 mins. only). All explanation from counselor not doctor felt like dr. just dropped in to agree w/findings was thinking I was schedule w/doctor instead of counselor who is very knowledgeable & helpful.

Sep 2019

•

Verified SHC Patient

Professional.

Mar 2019

•

Verified SHC Patient

Dr. James Ford and Rechelle Reyes were really helpful in helping us understand what kind of treatment my mom needed. We appreciate the recommendation and advice and quick responses in communication.

Oct 2018

•

Verified SHC Patient

I felt like the doctors weren't explaining genetics to me in laymen's terms. It was overall very confusing and I felt like no one showed genuine concern for being a 30 yr. old with a very rare cancer.

Aug 2018

•

Verified SHC Patient

Dr. Ford & PA Rachelle were excellent.

Jan 2018

•

Verified SHC Patient

Dr. Ford & Rachel Koff spent a significant amt. of time with me explaining the testing process and what tests I would be having. Rachel spent a lot of time going over my history etc. Very friendly & professional. I was impressed!

Sep 2017

•

Verified SHC Patient

Dr. Ford and Rachel Koff were amazing at explaining the genetic condition I have even though there is not much known about it. I could tell that they had spent a great deal of time preparing for my appointment.

Aug 2017

•

Verified SHC Patient

Good.

Apr 2017

•

Verified SHC Patient

Once again, very impressed, and I am fairly hard to impress.

Mar 2017

•

Verified SHC Patient

As a longtime healthcare employee - Dr. Shith and her team could not do better!

Feb 2017

•

Verified SHC Patient

Dr. Ford was very professional & explained my condition very well.

Oct 2016

•

Verified SHC Patient

Dr. Ford and his PA Rochelle Ryes are wonderful. They have spent time with me and explained things in detail. Made sure I was plugged in to many other resources, palliative care, nutrition, etc.

Apr 2016

•

Verified SHC Patient

Both Dr. Ford & Rochelle Reyes are amazing. We learn a lot and feel well taken care of. Every thing is clear and next steps are reviewed thoroughly.

Mar 2016

•

Verified SHC Patient

The provider went over a power point type presentation which included an enormous amount of information & I would have loved to have been given a copy of it to read but I left with no pamphlets or reading material bat. genetic testing. I had to go home & Google the few things I remembered from our discussion.

Nov 2015

•

Verified SHC Patient

Genetic counselor was extremely professional.

Oct 2015

•

Verified SHC Patient

Everything was perfect.

Sep 2015

•

Verified SHC Patient

Excellent.

Dec 2014

•

Verified SHC Patient

I felt that despite telling me "I reviewed your information prior to your visit" it was clear he maybe glanced at it only. He seemed VERY anxious to leave room & go to next patient.

Apr 2014

•

Verified SHC Patient

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

James Ford

Medical oncologist, Gastrointestinal specialist, Cancer geneticist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

GI Cancer Prevention Program in Redwood City Redwood City, CA

GI Cancer Prevention Program in Redwood City

Important Information about Our Organizations and Physician Affiliation

Patient Reviews

(76 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

James Ford

Medical oncologist, Gastrointestinal specialist, Cancer geneticist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

GI Cancer Prevention Program in Redwood City Redwood City, CA

GI Cancer Prevention Program in Redwood City

Important Information about Our Organizations and Physician Affiliation

Patient Reviews

(76 reviews)

Referring Physicians

PHYSICIAN HELPLINE